NASDAQ
Corvus Pharmaceuticals, Inc. (CRVS)
♥ 419 Thanks from members
Corvus Pharmaceuticals (CRVS) exhibits a polarized market sentiment, balanced between strong clinical momentum for its lead ITK inhibitor soquelitinib—backed by a robust cash runway into 2028—and wider net losses driven by escalating research and development expenses.